Search

Displaying results 2251 - 2260 of 10000 in total
  1. Pathway

    Bezafibrate Action Pathway (New)

    smpdb.ca/view/SMP0125291
    Drug action

    Bezafibrate is a lipid-lowering fibrate used in the management of primary and secondary hyperlipidaemia, when there is a lack of clinical improvement following lifestyle modifications or correction of the underlying disorder. Bezafibrate...

    Drugs: Biotin · Magnesium cation · Bezafibrate
    Enzymes: Apolipoprotein B-100
  2. Drug

    Sodium bisulfite

    go.drugbank.com/drugs/DB14015
    ApprovedWithdrawn

    Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

    Mixtures: LIBAVIT-K 20 MG AMPUL, 5 ADET, NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETLICategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Lutropin alfa

    go.drugbank.com/drugs/DB00044
    ApprovedInvestigational

    Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. … In males, LH stimulates Leydig cell to produce testosterone.

    Mixtures: PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 10 ADET, PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETSynonyms: Recombinant LH
  4. Drug

    Florbetapir F-18

    go.drugbank.com/drugs/DB09149
    ApprovedInvestigational

    The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay. … Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide

  5. Drug

    XPro1595

    go.drugbank.com/drugs/DB16454
    Investigational

    XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.

    Synonyms: HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA., SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL
  6. Target

    Tumor necrosis factor receptor superfamily member 10B

    go.drugbank.com/bio_entities/BE0003433
    TargetHumans

    Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:10549288). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation wh...

    Polypeptides: Tumor necrosis factor receptor superfamily member 10B
  7. Target

    Tumor necrosis factor receptor superfamily member 10A

    go.drugbank.com/bio_entities/BE0010564
    TargetHumans

    Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:26457518, PubMed:38532423). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteoly...

    Polypeptides: Tumor necrosis factor receptor superfamily member 10A
  8. Drug

    Tilidine

    go.drugbank.com/drugs/DB13787
    Investigational

    Mixtures: TILIDIN 100/8 RETARD 1A PH, TILIDIN 100/8 RETARD 1A PH
  9. Drug

    Cobomarsen

    go.drugbank.com/drugs/DB14931
    Investigational

    Cobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).

  10. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETProducts: CEPROTIN 500 IU IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON